Histological improvement of long-term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels

Journal of Viral Hepatitis

Volumn 20, Issue 5, 2013, Pages 328-335

  Du, X ^a   Wang, J ^b   Shao, L ^b   Hu, X ^c   Yang, C ^a   Shen, L ^b   Weng, X ^b   Zhang, Wenhong ^b,c  

^a Beilun People's Hospital   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

antiviral therapy; fibrosis; hepatitis B; liver biopsy; normal alanine aminotransferase

Indexed keywords

ALANINE AMINOTRANSFERASE; LAMIVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; LONG TERM CARE; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT DURATION;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOPSY; FEMALE; HEPATITIS B, CHRONIC; HISTOCYTOCHEMISTRY; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876127693     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12034     Document Type: Article

References (25)

1. Lavanchy D,. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107. (Pubitemid 38365759)
2. Liaw YF, Chu CM,. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
3. Chen CJ, Yang HI, Su J, et al,. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. (Pubitemid 43042691)
4. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
5. Chen CJ, Yang HI, Iloeje UH, REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49: S72-S84.
6. Liu CJ, Chen BF, Chen PJ, et al,. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006; 193: 1258-1265.
7. Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K,. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2004; 19: 670-675. (Pubitemid 38858201)
8. Kumar M, Sarin SK, Hissar S, et al,. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134: 1376-1384. (Pubitemid 351615375)
9. McMahon BJ,. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45-S55.
10. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH,. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760-767. (Pubitemid 350051121)
11. Dienstag JL, Schiff ER, Wright TL, et al,. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263. (Pubitemid 29489740)
12. Lai CL, Chien RN, Leung NW, et al,. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68. (Pubitemid 28304879)
13. Suzuki Y, Kumada H, Ikeda K, et al,. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999; 30: 743-748. (Pubitemid 29248970)
14. Dienstag JL, Goldin RD, Heathcote EJ, et al,. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-117. (Pubitemid 36055344)
15. Rizzetto M, Tassopoulos NC, Goldin RD, et al,. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol 2005; 42: 173-179. (Pubitemid 40143462)
16. Yuen MF, Chow DH, Tsui K, et al,. Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment Pharmacol Ther 2005; 21: 841-849. (Pubitemid 40477244)
17. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ,. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-313. (Pubitemid 46374587)
18. Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al,. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011; 53: 1854-1863.
19. Scheuer PJ,. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
20. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi 2011; 19: 13-24.
21. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
22. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
23. Calvaruso V, Craxì A,. Fibrosis in chronic viral hepatitis. Best Pract Res Clin Gastroenterol 2011; 25: 219-230.
24. Chang TT, Liaw YF, Wu SS, et al,. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.
25. Schiff ER, Lee SS, Chao YC, et al,. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011; 9: 274-276.